

# Bit Market Services

Informazione Regolamentata n. 0472-30-2015	Data/Ora Ricezione 07 Luglio 2015 18:11:25	MTA - Star
--	--	------------

Societa' : BB BIOTECH

Identificativo : 60641

Informazione  
Regolamentata

Nome utilizzatore : BIOTECHNSS01 - Alderuccio

Tipologia : IRAG 10

Data/Ora Ricezione : 07 Luglio 2015 18:11:25

Data/Ora Inizio : 07 Luglio 2015 18:26:26

Diffusione presunta

Oggetto : BB Biotech AG earns after-tax profits of  
CHF 717 million in the first half-year 2015

*Testo del comunicato*

Vedi allegato.

Media Release, July 7, 2015

## **BB Biotech AG earns after-tax profits of CHF 717 million in the first half-year 2015**

In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information about its profits in the first half-year 2015.

Based on preliminary unaudited consolidated results, BB Biotech AG closed the past half-year with a profit of CHF 717 million (CHF 261 million in the corresponding period of the previous year).

The net profit figure for the first half-year 2015 reflects the fundamental strength of the biotech sector and the successful investment strategy pursued by BB Biotech with clearly defined areas of focus. BB Biotech's share price rose 21.5% in CHF respectively 38.7% in EUR during the half-year period.

The half-year report for 2015 will be published on July 17, 2015.

### **For further information:**

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland  
Tanja Chicherio, Tel. +41 44 267 67 07, [tch@bellevue.ch](mailto:tch@bellevue.ch)

### **Company profile**

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector with approx. CHF 3.7 billion in assets under management. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.

Fine Comunicato n.0472-30

Numero di Pagine: 3